

Reference Number: FOI202122401
From: Commercial
Date: 13 December 2021
Subject: Treatment of clotting disorders

Q1 How many patients has your trust treated (for any medical condition) in the past 3 months with the following drugs:

- a. Alphanate
- b. Alprolix
- c. BeneFIX
- d. HaemateP
- e. Idelvion
- f. Refixia
- g. Rixubis
- h. Veyvondi
- i. Voncento
- j. Wilate
- k. Willfact

A1

- a. Alphanate = 0
- b. Alprolix = 1
- c. BeneFIX = 1
- d. HaemateP = 0
- e. Idelvion = 0
- f. Refixia = 0
- g. Rixubis = 0
- h. Veyvondi = 0
- i. Voncento = 1
- j. Wilate = 0
- k. Willfact = 0

Q2 How many patients have been treated in the past 3 months with:

- a. Gene therapy for Haemophilia B ONLY
- b. Desmopressin for Von Willebrand (VWD) Disease ONLY
- c. Tranexamic Acid for Von Willebrand (VWD) Disease ONLY

A2

- a. Zero Haem B patients who have been treated with Gene therapy
- b. We have four VWD patients treated with Desmopressin ONLY
- c. Zero with Tranexamic acid ONLY

Q3 Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment:

- a. During surgery
- b. On-demand to treat bleeding episodes

A3 Information not held – there were no patients treated with Veyvondi

Q4 How many patients are registered with your Haemophilia Centre for:

- a. Von Willebrand Disease – adult patients (age 18 or above)
- b. Von Willebrand Disease – pediatric patients (age 17 or under)
- c. Haemophilia B (any age)

A4 We have 60 VWD patients.

- a. 2
- b. 58
- c. We have 5 Haem B patients.